Physician profile
Gregory J Brown
NPI 1821058181
$494,713.22
in general payments reported to CMS, 2019-2025
22 companies · $117K in 2025
The $117K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $8,789 · 2021: $77K · 2022: $61K · 2023: $95K · 2024: $81K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $215K · Honoraria: $27K · Consulting Fee: $22K · Travel and Lodging: $17K · Food and Beverage: $12K · Education: $21.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214,981.63 |
| Honoraria | $27,000.00 |
| Consulting Fee | $21,988.00 |
| Travel and Lodging | $17,215.54 |
| Food and Beverage | $11,966.78 |
| Education | $21.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $153,722.57 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $138,026.13 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $78,795.15 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $72,421.76 | 2021-2025 | Vraylar |
| Ironshore Pharmaceuticals INC. | $29,378.98 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $11,086.53 | 2022-2024 | Quviviq |
| Corium, LLC | $4,029.45 | 2022-2025 | Azstarys, Azstarys |
| Allergan, INC. | $1,864.30 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,274.68 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,049.94 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $680.04 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $630.56 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $521.57 | 2019-2022 | |
| Axsome Therapeutics, INC. | $448.19 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $205.71 | 2024-2025 | Cobenfy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $180.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $176.51 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $108.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $48.00 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $28.82 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.82 | 2019 | |
| Neos Therapeutics, Lp | $16.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.